Effect of nicorandil in patients with heart failure: A systematic review and meta-analysis

Cardiovascular Therapeutics

Volumn 32, Issue 6, 2014, Pages 283-296

  Zhao, Fujie ^a   Chaugai, Sandip ^a   Chen, Peng ^a   Wang, Yan ^a   Wang, Dao Wen ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Hypertension; Ischemic heart disease; Molecular cardio biology; Vascular biology

Indexed keywords

NICORANDIL; VASODILATOR AGENT;

BLOOD PRESSURE; CORONARY ARTERY BLOOD FLOW; DRUG EFFECTS; HEART FAILURE; HEART RATE; HUMAN; META ANALYSIS; PATHOLOGY; PATHOPHYSIOLOGY;

BLOOD PRESSURE; CORONARY CIRCULATION; HEART FAILURE; HEART RATE; HUMANS; NICORANDIL; VASODILATOR AGENTS;

EID: 84911414892     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12097     Document Type: Article

References (50)

1. Fang J, Mensah GA, Croft JB, Keenan NL. Heart failure-related hospitalization in the U.S.1979 to 2004. J Am Coll Cardiol 2008;52:428-434.
2. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European society of cardiology Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-1847.
3. Das B, Sarkar C. Cardiomyocyte mitochondrial KATP channels participate in the antiarrhythmic and antiinfarct effects of KATP activators during ischemia and reperfusion in an intact anesthetized rabbit model. Pol J Pharmacol 2003;55:771-786.
4. Ozcan C, Bienengraeber M, Dzeja PP, Terzic A. Potassium channel openers protect cardiac mitochondria by attenuating oxidant stress at reoxygenation. Am J Physiol Heart Circ Physiol 2002;282:H531-H539.
5. Mano T, Shinohara R, Nagasaka A, et al. Scavenging effect of nicorandil on free radicals and lipid peroxide in streptozotocin-induced diabetic rats. Metabolism 2000;49:427-431.
6. Gross G, Pieper G, Farber NE, Warltier D, Hardman H. Effects of nicorandil on coronary circulation and myocardial ischemia. Am J Cardiol 1989;63:11J-17J.
7. Fukuda H, Luo CS, Gu X, Guo LL, Digerness SB, Li JX, Pike MM. The effect of K(atp)channel activation on myocardial cationic and energetic status during ischemia and reperfusion: role in cardioprotection. J Mol Cell Cardiol 2001;33:545-560.
8. Ishida H, Higashijima N, Hirota Y, Genka C, Nakazawa H, Nakaya H, Sato T. Nicorandil attenuates the mitochondrial Ca2 + overload with accompanying depolarization of the mitochondrial membrane in the heart. Naunyn Schmiedebergs Arch Pharmacol 2004;369:192-197.
9. Nichols CG, Lederer WJ. Adenosine triphosphate-sensitive potassium channels in the cardiovascular system. Am J Physiol 1991;261:H1675-H1686.
10. Hongo M, Mawatari E, Sakai A, et al. Effects of nicorandil on monocrotaline-induced pulmonary arterial hypertension in rats. J Cardiovasc Pharmacol 2005;46:452-458.
11. Kawamura T, Kadosaki M, Nara N, Wei J, Endo S, Inada K. Nicorandil attenuates NF-kappaB activation, adhesion molecule expression, and cytokine production in patients with coronary artery bypass surgery. Shock 2005;24:103-108.
12. Date T, Taniguchi I, Inada K, et al. Nicorandil inhibits serum starvation-induced apoptosis in vascular endothelial cells. J Cardiovasc Pharmacol 2005;46:721-726.
13. Abdel-Raheem IT, Taye A, Abouzied MM. Cardioprotective effects of nicorandil, a mitochondrial potassium channel opener against doxorubicin-induced cardiotoxicity in rats. Basic Clin Pharmacol Toxicol 2013;113:158-166.
14. Nishikawa S, Tatsumi T, Shiraishi J, et al. Nicorandil regulates Bcl-2 family proteins and protects cardiac myocytes against hypoxia-induced apoptosis. J Mol Cell Cardiol 2006;40:510-519.
15. Tsuchida A, Miura T, Tanno M, et al. Infarct size limitation by nicorandil: roles of mitochondrial K(ATP) channels, sarcolemmal K(ATP) channels, and protein kinase C. J Am Coll Cardiol 2002;40:1523-1530.
16. Lee TM, Su SF, Chou TF, Lee YT, Tsai CH. Loss of preconditioning by attenuated activation of myocardial ATP-sensitive potassium channels in elderly patients undergoing coronary angioplasty. Circulation 2002;105:334-340.
17. Lu C, Minatoguchi S, Arai M, et al. Nicorandil improves post-ischemic myocardial dysfunction in association with opening the mitochondrial K(ATP) channels and decreasing hydroxyl radicals in isolated rat hearts. Circulation 2006;J70:1650-1654.
18. Lee HL, Chang PC, Chou CC, et al. Blunted proarrhythmic effect of nicorandil in a Langendorff-perfused phase-2 myocardial infarction rabbit model. Pacing Clin Electrophysiol 2013;36:142-151.
19. Das B, Sarkar C. Is the sarcolemmal or mitochondrial K(ATP) channel activation important in the antiarrhythmic and cardioprotective effects during acute ischemia/reperfusion in the intact anesthetized rabbit model? Life Sci 2005;77:1226-1248.
20. Das B, Sarkar C. Mitochondrial K ATP channel activation is important in the antiarrhythmic and cardioprotective effects of non-hypotensive doses of nicorandil and cromakalim during ischemia/reperfusion: a study in an intact anesthetized rabbit model. Pharmacol Res 2003;47:447-461.
21. Okamura A, Rakugi H, Ohishi M, et al. Additive effects of nicorandil on coronary blood flow during continuous administration of nitroglycerin. J Am Coll Cardiol 2001;37:719-725.
22. Ito H, Taniyama Y, Iwakura K, et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol 1999;33:654-660.
23. Zhao JL, Yang YJ, Chen JL, Kang LM, Wu Y, Gao RL. Nicorandil reduces myocardial no-reflow by protection of endothelial function via the activation of KATP channel. Clin Chim Acta 2006;374:100-105.
24. Gross GJ, Pieper GM, Warltier DC. Comparative effects of nicorandil, nitroglycerin, nicotinic acid, and SG-86 on the metabolic status and functional recovery of the ischemic-reperfused myocardium. J Cardiovasc Pharmacol 1987;10(Suppl 8):S76-S84.
25. Abiko Y, Ichihara K, Sakai K. Effects of nicorandil and other antianginal drugs on myocardial pH in the ischemic dog heart. J Cardiovasc Pharmacol 1987;10(Suppl 8):S85-S91.
26. Doring G. Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients. J Cardiovasc Pharmacol 1992;20(Suppl 3):S74-S81.
27. Shirakabe A, Hata N, Yokoyama S, Shinada T, Kobayashi N, Asai K, Mizuno K. Efficacy and safety of nicorandil therapy in patients with acute heart failure. J Cardiol 2010;56:339-347.
28. Yamada T, Okuyama Y, Morita T, et al. Long-term nicorandil therapy reverses left ventricular remodeling in patients with chronic heart failure: a randomized placebo-controlled study. Circulation 2009;120:S887.
29. Tsutamoto T, Kinoshita M, Nakae I, Maeda Y, Wada A, Yabe T, Horie H. Absence of hemodynamic tolerance to nicorandil in patients with severe congestive heart failure. Am Heart 1994;J127:866-873.
30. Tsutamoto T, Kinoshita M, Hisanaga T, et al. Comparison of hemodynamic effects and plasma cyclic guanosine monophosphate of nicorandil and nitroglycerin in patients with congestive heart failure. Am J Cardiol 1995;75:1162-1165.
31. Larsen AI, Goransson L, Aarsland T, Tamby JF, Dickstein K. Comparison of the degree of hemodynamic tolerance during intravenous infusion of nitroglycerin versus nicorandil in patients with congestive heart failure. Am Heart 1997;J134:435-441.
32. Hattori H, Minami Y, Mizuno M, et al. Differences in hemodynamic responses between intravenous carperitide and nicorandil in patients with acute heart failure syndromes. Heart Vessels 2013;28:345-351.
33. Choi D. Clinical evaluation of 48 hr-intravenous nicorandil infusion in AHF. The Phase III study.
34. Kasama S, Toyama T, Hatori T, et al. Comparative effects of nicorandil with isosorbide mononitrate on cardiac sympathetic nerve activity and left ventricular function in patients with ischemic cardiomyopathy. Am Heart J 2005;150:477.
35. Galie N, Varani E, Maiello L, Boriani G, Boschi S, Binetti G, Magnani B. Usefulness of nicorandil in congestive heart failure. Am J Cardiol 1990;65:343-348.
36. Shigekiyo M, Harada K. Impact of nicorandil on renal function in patients with acute heart failure and pre-existing renal dysfunction. Eur Heart J (2012) 33(Abstract Supplement), 7-8.
37. Shigekiyo M, Harada K, Okada A, et al. Intravenous nicorandil improves symptoms and left ventricular diastolic function immediately in patients with acute heart failure: a randomized, controlled trial. Eur Heart J 2011 32(Abstract Supplement), 963.
38. Ishihara S, Koga T, Kaseda S, et al. Effects of intravenous nicorandil on the mid-term prognosis of patients with acute heart failure syndrome. Circulation 2012;J76:1169-1176.
39. Kasama S, Toyama T, Iwasaki T, et al. Effects of oral nicorandil therapy on sympathetic nerve activity and cardiac events in patients with chronic heart failure: subanalysis of our previous report using propensity score matching. Eur J Nucl Med Mol Imaging 2014;41:144-154.
40. Yokota M, Horisawa T, Iwase M, et al. Effects of a new vasodilator, nicorandil, on exercise-induced impairment of left ventricular function in patients with old myocardial infarction. J Cardiovasc Pharmacol 1987;10(Suppl 8):S116-S122.
41. Minami Y, Nagashima M, Kajimoto K, Shiga T, Hagiwara N. Acute efficacy and safety of intravenous administration of nicorandil in patients with acute heart failure syndromes: usefulness of noninvasive echocardiographic hemodynamic evaluation. J Cardiovasc Pharmacol 2009;54:335-340.
42. Tanaka K, Kato K, Takano T, et al. Acute effects of intravenous nicorandil on hemodynamics in patients hospitalized with acute decompensated heart failure. J Cardiol 2010;56:291-299.
43. Kunishige M, Ishizuka S, Ikeoka K, et al. Intravenous nicorandil therapy reduces matrix metalloproteinase-2 in patients with acute heart failure syndromes. J Am Coll Cardiol 2011;57:E257.
44. Tokita Y, Sato N, Munakata R, et al. Intravenous bolus administration of nicorandil improves myocardial perfusion in patients with acute ischemic heart failure. Eur Heart J 2010;31:852.
45. Giles TD, Pina IL, Quiroz AC, et al. Hemodynamic and neurohumoral responses to intravenous nicorandil in congestive heart failure in humans. J Cardiovasc Pharmacol 1992;20:572-578.
46. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-328.
47. Takahide N, Kazuhiko N, Arihiro H, Takuma A, Masanori K, Shinya M. Effectiveness of nicorandil, a K-ATP channel opener, against contrast-induced nephropathy after percutaneous coronary intervention in patients with poor renal function. Circulation 2011;124:A12180.
48. Kishi T. Effects of nicorandil bolus injection alone of on renal function in patients with 'Clinical Scenario 1' acute heart failure. Therap Res 2011;32:303-310.
49. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009;6:e1000100.
50. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.